Načítá se...
Efficacy and safety of oral sildenafil in children with Down syndrome and pulmonary hypertension
BACKGROUND: Despite the increased risk for pulmonary hypertension in children with Down syndrome, the response to treatment with targeted therapies for pulmonary hypertension in these patients is not well characterized. The Sildenafil in Treatment-naive children, Aged 1–17 years, with pulmonary arte...
Uloženo v:
| Vydáno v: | BMC Cardiovasc Disord |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5496590/ https://ncbi.nlm.nih.gov/pubmed/28676038 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12872-017-0569-3 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|